Sally C. Pipes

Commentary

Don’t believe the CBO’s spin on the One Big Beautiful Bill Act

In a recent letter to top Democrats, the Congressional Budget Office claimed that the Republicans’ One Big Beautiful Bill Act would kick millions of people off their health insurance. That warning is misleading. Millions of people are improperly enrolled in Medicaid and taxpayer-subsidized plans through Obamacare’s exchanges. Republicans are rightly ...
Commentary

This Groundbreaking Insurance Reform Is Buried In The One Big, Beautiful Bill

The legislative package would codify and expand Individual Coverage Health Reimbursement Arrangements, which the first Trump administration introduced in 2019. ICHRAs allow employers to give workers untaxed dollars, which they can use to purchase health insurance on the individual market. In many ways, ICHRAs are the health insurance equivalent of retirement accounts to ...
Drug Pricing

D.C.’s Embrace of Price Controls Bad News for Patients

President Trump announced his intention last month to peg U.S. drug prices to those that foreign governments have set within their borders. The very same day, federal officials said they’d reveal in February 2026 a list of 15 drugs subject to price controls through Medicare’s Part B outpatient benefit and ...
Blog

Read the latest on the push for single-payer health care

What’s Wrong With Single-Payer? Ask Vermont.

In 2011, Vermont created Green Mountain Care, “a publicly financed health care program designed to contain costs and to provide comprehensive, affordable, high-quality health care coverage for all Vermont residents.” But the initiative didn’t last long. Estimates suggested the program would cost between $1.6 and $2.5 billion in just its ...
Commentary

America Shouldn’t Buy Into Single-Payer Mirage

Will the seventh time be the charm? Sen. Bernie Sanders sure hopes so. Vermont’s senior senator just introduced his latest bid to install Medicare for All in the United States. In seven of the last eight Congresses, dating back to 2011, he’s offered legislation to launch a government takeover of ...
Commentary

Potential Tariffs Will Harm Patients In The Name Of Protecting Them

Two months ago, the Commerce Department launched an investigation into whether pharmaceutical imports pose a threat to national security (i.e., a Section 232 investigation). Not only are the investigation’s accusations groundless, implementing the proposed remedy – more tariffs – will create the very problems that the investigation hopes to avoid. ...
Commentary

Away With Provider Taxes

The Centers for Medicare & Medicaid Services recently published a rule targeting “provider taxes,” a financing gimmick states use to harvest extra Medicaid dollars from the federal government. Good on the Trump administration. Over the last decade and a half, states have exploited provider taxes and other financing loopholes to ...
Commentary

Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Blog

Don’t Take Cutting-Edge Drugs for Granted

It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Commentary

Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans

Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Commentary

Don’t believe the CBO’s spin on the One Big Beautiful Bill Act

In a recent letter to top Democrats, the Congressional Budget Office claimed that the Republicans’ One Big Beautiful Bill Act would kick millions of people off their health insurance. That warning is misleading. Millions of people are improperly enrolled in Medicaid and taxpayer-subsidized plans through Obamacare’s exchanges. Republicans are rightly ...
Commentary

This Groundbreaking Insurance Reform Is Buried In The One Big, Beautiful Bill

The legislative package would codify and expand Individual Coverage Health Reimbursement Arrangements, which the first Trump administration introduced in 2019. ICHRAs allow employers to give workers untaxed dollars, which they can use to purchase health insurance on the individual market. In many ways, ICHRAs are the health insurance equivalent of retirement accounts to ...
Drug Pricing

D.C.’s Embrace of Price Controls Bad News for Patients

President Trump announced his intention last month to peg U.S. drug prices to those that foreign governments have set within their borders. The very same day, federal officials said they’d reveal in February 2026 a list of 15 drugs subject to price controls through Medicare’s Part B outpatient benefit and ...
Blog

Read the latest on the push for single-payer health care

What’s Wrong With Single-Payer? Ask Vermont.

In 2011, Vermont created Green Mountain Care, “a publicly financed health care program designed to contain costs and to provide comprehensive, affordable, high-quality health care coverage for all Vermont residents.” But the initiative didn’t last long. Estimates suggested the program would cost between $1.6 and $2.5 billion in just its ...
Commentary

America Shouldn’t Buy Into Single-Payer Mirage

Will the seventh time be the charm? Sen. Bernie Sanders sure hopes so. Vermont’s senior senator just introduced his latest bid to install Medicare for All in the United States. In seven of the last eight Congresses, dating back to 2011, he’s offered legislation to launch a government takeover of ...
Commentary

Potential Tariffs Will Harm Patients In The Name Of Protecting Them

Two months ago, the Commerce Department launched an investigation into whether pharmaceutical imports pose a threat to national security (i.e., a Section 232 investigation). Not only are the investigation’s accusations groundless, implementing the proposed remedy – more tariffs – will create the very problems that the investigation hopes to avoid. ...
Commentary

Away With Provider Taxes

The Centers for Medicare & Medicaid Services recently published a rule targeting “provider taxes,” a financing gimmick states use to harvest extra Medicaid dollars from the federal government. Good on the Trump administration. Over the last decade and a half, states have exploited provider taxes and other financing loopholes to ...
Commentary

Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives

Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Blog

Don’t Take Cutting-Edge Drugs for Granted

It’s hard to imagine a more destructive plan. Importing foreign price controls on prescription drugs would reduce access to existing treatments for everything from rare diseases to cancer. To understand why, consider two recent pieces by Michael Baker for the American Action Forum’s “Reality Check-Up: The Truth About Single-Payer Systems.” ...
Commentary

Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans

Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Scroll to Top